Zhittya Genesis Medicine Announces New Clinical Trials, New FGF-1 and New Research and Development
Over the last seven years Zhittya Genesis Medicine has advanced far ahead of any competition. Zhittya Genesis Medicine has started Phase I Clinical Trials in Parkinson's Disease and ALS. Zhittya Genesis Medicine has created a new batch of FGF-1 allowing them to progress through clinical trials, bringing them closer to hopeful approval. Zhittya Genesis Medicine has begun research into other diseases to see if FGF-1 could possibly affect the outcomes of sufferers from diseases such as Autism.
It's no wonder since Dan Montano is the CEO of Zhittya Genesis Medicine.
Zhittya Genesis Medicine CEO, Daniel C. Montano founded Cardiovascular BioTherapeutics. Zhittya Genesis Medicine CEO, Daniel C. Montano, raised all the money when he was CEO of CVBT. Zhittya Genesis Medicine CEO, Daniel C. Montano oversaw all of the clinical trials when he was CEO of CVBT.
Since Dan Montano left, CVBT has done nothing. Since Dan Montano left, CVBT/VT has conducted: NO CLINICAL TRIALS, HAS LOST EVERY LAWSUIT, HAS PRODUCED NO FGF-1, HAS RAISED NO MONEY, HAS MADE NO PRESENTATIONS, AND HAS NEVER SENT OUT ANY CORPORATE INFORMATION.
Seven years without Dan Montano and CVBT/VT has done nothing.
